Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

High-throughput screening of antibiotic-resistant bacteria in picodroplets.

Liu X, Painter RE, Enesa K, Holmes D, Whyte G, Garlisi CG, Monsma FJ, Rehak M, Craig FF, Smith CA.

Lab Chip. 2016 Apr 26;16(9):1636-43. doi: 10.1039/c6lc00180g.

PMID:
27033300
2.

A Diffusion-Based and Dynamic 3D-Printed Device That Enables Parallel in Vitro Pharmacokinetic Profiling of Molecules.

Lockwood SY, Meisel JE, Monsma FJ Jr, Spence DM.

Anal Chem. 2016 Feb 2;88(3):1864-70. doi: 10.1021/acs.analchem.5b04270. Epub 2016 Jan 15.

3.

HIV cell fusion assay: phenotypic screening tool for the identification of HIV entry inhibitors via CXCR4.

Smith EB, Ogert RA, Pechter D, Villafania A, Abbondanzo SJ, Lin K, Rivera-Gines A, Rebsch-Mastykarz C, Monsma FJ Jr.

J Biomol Screen. 2014 Jan;19(1):108-18. doi: 10.1177/1087057113500074. Epub 2013 Aug 29.

PMID:
23989454
4.

Murgocil is a highly bioactive staphylococcal-specific inhibitor of the peptidoglycan glycosyltransferase enzyme MurG.

Mann PA, Müller A, Xiao L, Pereira PM, Yang C, Ho Lee S, Wang H, Trzeciak J, Schneeweis J, Dos Santos MM, Murgolo N, She X, Gill C, Balibar CJ, Labroli M, Su J, Flattery A, Sherborne B, Maier R, Tan CM, Black T, Onder K, Kargman S, Monsma FJ Jr, Pinho MG, Schneider T, Roemer T.

ACS Chem Biol. 2013 Nov 15;8(11):2442-51. doi: 10.1021/cb400487f. Epub 2013 Sep 5.

PMID:
23957438
5.

SCH 1473759, a novel Aurora inhibitor, demonstrates enhanced anti-tumor activity in combination with taxanes and KSP inhibitors.

Basso AD, Liu M, Gray K, Tevar S, Lee S, Liang L, Ponery A, Smith EB, Monsma FJ Jr, Yu T, Zhang Y, Kerekes AD, Esposite S, Xiao Y, Tagat JR, Hicklin DJ, Kirschmeier P.

Cancer Chemother Pharmacol. 2011 Oct;68(4):923-33. doi: 10.1007/s00280-011-1568-1. Epub 2011 Feb 5.

PMID:
21298383
6.

Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening.

Cavasotto CN, Orry AJ, Murgolo NJ, Czarniecki MF, Kocsi SA, Hawes BE, O'Neill KA, Hine H, Burton MS, Voigt JH, Abagyan RA, Bayne ML, Monsma FJ Jr.

J Med Chem. 2008 Feb 14;51(3):581-8. doi: 10.1021/jm070759m. Epub 2008 Jan 17.

PMID:
18198821
7.

P518/Qrfp sequence polymorphisms in SAMP6 osteopenic mouse.

Zhang Q, Qiu P, Arreaza MG, Simon JS, Golovko A, Laverty M, Vassileva G, Gustafson EL, Rojas-Triana A, Bober LA, Hedrick JA, Monsma FJ Jr, Greene JR, Bayne ML, Murgolo NJ.

Genomics. 2007 Nov;90(5):629-35. Epub 2007 Sep 17.

8.

The KiSS-1 receptor GPR54 is essential for the development of the murine reproductive system.

Funes S, Hedrick JA, Vassileva G, Markowitz L, Abbondanzo S, Golovko A, Yang S, Monsma FJ, Gustafson EL.

Biochem Biophys Res Commun. 2003 Dec 26;312(4):1357-63.

PMID:
14652023
9.

Cloning and characterization of murine neuromedin U receptors.

Funes S, Hedrick JA, Yang S, Shan L, Bayne M, Monsma FJ Jr, Gustafson EL.

Peptides. 2002 Sep;23(9):1607-15.

PMID:
12217421
10.

Molecular modeling and site-specific mutagenesis of the histamine-binding site of the histamine H4 receptor.

Shin N, Coates E, Murgolo NJ, Morse KL, Bayne M, Strader CD, Monsma FJ Jr.

Mol Pharmacol. 2002 Jul;62(1):38-47.

11.

Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs.

Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma FJ Jr, Wiekowski MT, Abbondanzo SJ, Cook DN, Bayne ML, Lira SA, Chintala MS.

J Clin Invest. 2001 Jun;107(12):1591-8.

12.

Cloning and characterization of a novel human histamine receptor.

Morse KL, Behan J, Laz TM, West RE Jr, Greenfeder SA, Anthes JC, Umland S, Wan Y, Hipkin RW, Gonsiorek W, Shin N, Gustafson EL, Qiao X, Wang S, Hedrick JA, Greene J, Bayne M, Monsma FJ Jr.

J Pharmacol Exp Ther. 2001 Mar;296(3):1058-66.

13.

High-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor.

Röver S, Adam G, Cesura AM, Galley G, Jenck F, Monsma FJ Jr, Wichmann J, Dautzenberg FM.

J Med Chem. 2000 Apr 6;43(7):1329-38.

PMID:
10753470
14.

ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999.

Zhang FL, Luo L, Gustafson E, Lachowicz J, Smith M, Qiao X, Liu YH, Chen G, Pramanik B, Laz TM, Palmer K, Bayne M, Monsma FJ Jr.

J Biol Chem. 2001 Mar 16;276(11):8608-15. Epub 2000 Dec 4.

15.

Identification of a novel neuromedin U receptor subtype expressed in the central nervous system.

Shan L, Qiao X, Crona JH, Behan J, Wang S, Laz T, Bayne M, Gustafson EL, Monsma FJ Jr, Hedrick JA.

J Biol Chem. 2000 Dec 15;275(50):39482-6.

16.

Identification of a human gastrointestinal tract and immune system receptor for the peptide neuromedin U.

Hedrick JA, Morse K, Shan L, Qiao X, Pang L, Wang S, Laz T, Gustafson EL, Bayne M, Monsma FJ Jr.

Mol Pharmacol. 2000 Oct;58(4):870-5.

17.

Residues in transmembrane regions III and VI contribute to the 5-ht6 receptor ligand binding site.

Boess FG, Monsma FJ Jr, Bourson A, Zwingelstein C, Sleight AJ.

Ann N Y Acad Sci. 1998 Dec 15;861:242-3. No abstract available.

PMID:
9928266
19.

Creating a functional opioid alkaloid binding site in the orphanin FQ receptor through site-directed mutagenesis.

Meng F, Ueda Y, Hoversten MT, Taylor LP, Reinscheid RK, Monsma FJ, Watson SJ, Civelli O, Akil H.

Mol Pharmacol. 1998 Apr;53(4):772-7.

20.

Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress.

Jenck F, Moreau JL, Martin JR, Kilpatrick GJ, Reinscheid RK, Monsma FJ Jr, Nothacker HP, Civelli O.

Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14854-8.

21.

Structures that delineate orphanin FQ and dynorphin A pharmacological selectivities.

Reinscheid RK, Higelin J, Henningsen RA, Monsma FJ Jr, Civelli O.

J Biol Chem. 1998 Jan 16;273(3):1490-5.

22.

Labelling of CRF1 and CRF2 receptors using the novel radioligand, [3H]-urocortin.

Gottowik J, Goetschy V, Henriot S, Kitas E, Fluhman B, Clerc RG, Moreau JL, Monsma FJ, Kilpatrick GJ.

Neuropharmacology. 1997 Oct;36(10):1439-46.

PMID:
9423932
23.

Interaction of tryptamine and ergoline compounds with threonine 196 in the ligand binding site of the 5-hydroxytryptamine6 receptor.

Boess FG, Monsma FJ Jr, Meyer V, Zwingelstein C, Sleight AJ.

Mol Pharmacol. 1997 Sep;52(3):515-23.

24.

Interaction of [3H]orphanin FQ and 125I-Tyr14-orphanin FQ with the orphanin FQ receptor: kinetics and modulation by cations and guanine nucleotides.

Ardati A, Henningsen RA, Higelin J, Reinscheid RK, Civelli O, Monsma FJ Jr.

Mol Pharmacol. 1997 May;51(5):816-24.

25.

Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells.

Boess FG, Monsma FJ Jr, Carolo C, Meyer V, Rudler A, Zwingelstein C, Sleight AJ.

Neuropharmacology. 1997 Apr-May;36(4-5):713-20.

PMID:
9225298
26.

Moving from the orphanin FQ receptor to an opioid receptor using four point mutations.

Meng F, Taylor LP, Hoversten MT, Ueda Y, Ardati A, Reinscheid RK, Monsma FJ, Watson SJ, Civelli O, Akil H.

J Biol Chem. 1996 Dec 13;271(50):32016-20.

27.

Rats rapidly develop tolerance to the locomotor-inhibiting effects of the novel neuropeptide orphanin FQ.

Devine DP, Taylor L, Reinscheid RK, Monsma FJ Jr, Civelli O, Akil H.

Neurochem Res. 1996 Nov;21(11):1387-96.

PMID:
8947929
29.

Primary structure and tissue distribution of the orphanin FQ precursor.

Nothacker HP, Reinscheid RK, Mansour A, Henningsen RA, Ardati A, Monsma FJ Jr, Watson SJ, Civelli O.

Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8677-82.

30.

The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion.

Devine DP, Reinscheid RK, Monsma FJ Jr, Civelli O, Akil H.

Brain Res. 1996 Jul 15;727(1-2):225-9.

PMID:
8842403
31.

Structure-activity relationship studies on the novel neuropeptide orphanin FQ.

Reinscheid RK, Ardati A, Monsma FJ Jr, Civelli O.

J Biol Chem. 1996 Jun 14;271(24):14163-8.

32.

Effects of altered 5-ht6 expression in the rat: functional studies using antisense oligonucleotides.

Sleight AJ, Monsma FJ Jr, Borroni E, Austin RH, Bourson A.

Behav Brain Res. 1996;73(1-2):245-8.

PMID:
8788511
33.

Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor.

Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FJ Jr, Civelli O.

Science. 1995 Nov 3;270(5237):792-4.

PMID:
7481766
34.

Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides.

Bourson A, Borroni E, Austin RH, Monsma FJ Jr, Sleight AJ.

J Pharmacol Exp Ther. 1995 Jul;274(1):173-80.

PMID:
7616396
35.

Molecular cloning of a novel G protein-coupled receptor related to the opiate receptor family.

Lachowicz JE, Shen Y, Monsma FJ Jr, Sibley DR.

J Neurochem. 1995 Jan;64(1):34-40.

PMID:
7798930
36.

Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.

Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR.

J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10.

PMID:
7908055
37.

Transfected D2 short dopamine receptors inhibit voltage-dependent potassium current in neuroblastoma x glioma hybrid (NG108-15) cells.

Castellano MA, Liu LX, Monsma FJ Jr, Sibley DR, Kapatos G, Chiodo LA.

Mol Pharmacol. 1993 Sep;44(3):649-56.

PMID:
8371717
38.

Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype.

Shen Y, Monsma FJ Jr, Metcalf MA, Jose PA, Hamblin MW, Sibley DR.

J Biol Chem. 1993 Aug 25;268(24):18200-4.

39.

Synthesis and processing of D2 dopamine receptors.

David C, Fishburn CS, Monsma FJ Jr, Sibley DR, Fuchs S.

Biochemistry. 1993 Aug 17;32(32):8179-83.

PMID:
8347618
40.

Organ specificity of the dopamine1 receptor/adenylyl cyclase coupling defect in spontaneously hypertensive rats.

Felder RA, Kinoshita S, Ohbu K, Mouradian MM, Sibley DR, Monsma FJ Jr, Minowa T, Minowa MT, Canessa LM, Jose PA.

Am J Physiol. 1993 Apr;264(4 Pt 2):R726-32.

PMID:
8476116
41.

Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.

Monsma FJ Jr, Shen Y, Ward RP, Hamblin MW, Sibley DR.

Mol Pharmacol. 1993 Mar;43(3):320-7.

PMID:
7680751
42.

Expression of dopamine D1A receptor gene in proximal tubule of rat kidneys.

Yamaguchi I, Jose PA, Mouradian MM, Canessa LM, Monsma FJ Jr, Sibley DR, Takeyasu K, Felder RA.

Am J Physiol. 1993 Feb;264(2 Pt 2):F280-5.

PMID:
8447437
43.

Molecular neurobiology of dopaminergic receptors.

Sibley DR, Monsma FJ Jr, Shen Y.

Int Rev Neurobiol. 1993;35:391-415. Review.

PMID:
8463063
44.

Characterization of the 5' flanking region of the human D1A dopamine receptor gene.

Minowa MT, Minowa T, Monsma FJ Jr, Sibley DR, Mouradian MM.

Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3045-9. Erratum in: Proc Natl Acad Sci U S A 1992 May 1;89(9):4220.

45.

Molecular neurobiology of dopamine receptor subtypes.

Sibley DR, Monsma FJ Jr, McVittie LD, Gerfen CR, Burch RM, Mahan LC.

Neurochem Int. 1992 Mar;20 Suppl:17S-22S. Review. No abstract available.

PMID:
1365419
46.

Molecular biology of dopamine receptors.

Sibley DR, Monsma FJ Jr.

Trends Pharmacol Sci. 1992 Feb;13(2):61-9. Review.

PMID:
1561715
47.

Regulation of D1A and D2 dopamine receptor mRNA during ontogenesis, lesion and chronic antagonist treatment.

Xu SX, Monsma FJ Jr, Sibley DR, Creese I.

Life Sci. 1992;50(5):383-96.

PMID:
1732708
48.

Cloning and expression of an A1 adenosine receptor from rat brain.

Mahan LC, McVittie LD, Smyk-Randall EM, Nakata H, Monsma FJ Jr, Gerfen CR, Sibley DR.

Mol Pharmacol. 1991 Jul;40(1):1-7.

PMID:
1857334
49.

Multiple fluorescent ligands for dopamine receptors. I. Pharmacological characterization and receptor selectivity.

Barton AC, Kang HC, Rinaudo MS, Monsma FJ Jr, Stewart-Fram RM, Macinko JA Jr, Haugland RP, Ariano MA, Sibley DR.

Brain Res. 1991 May 3;547(2):199-207.

PMID:
1679366
50.

Transfected D2 dopamine receptors mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells.

Kanterman RY, Mahan LC, Briley EM, Monsma FJ Jr, Sibley DR, Axelrod J, Felder CC.

Mol Pharmacol. 1991 Mar;39(3):364-9.

PMID:
1848657

Supplemental Content

Loading ...
Support Center